Garrido A, Brunet S, Calabuig M, et al. Final results of the CETLAM LAM-203 trial fort he treatment of primary AML up tot the age of 70. EHA 2017, abstract S790.
Lager risico op abnormaal uterien bloedverlies met dabigatran ten opzichte van warfarine
jan 2017